Europe Veterinary Castration Market

The Europe veterinary castration market is projected to reach USD 68.2 million by 2032 from USD 45.6 million in 2026, at a CAGR of 6.9%.

The Europe veterinary castration market is growing steadily, driven by rising focus on animal welfare, stray population control, and responsible pet ownership across countries such as Germany, France, and Spain. The increasing adoption of non-surgical methods such as immunocastration vaccines and hormonal implants is reducing reliance on traditional surgeries. Regulatory support from the European Union, especially in livestock sectors such as swine, along with the expansion of sterilization programs by governments and NGOs, is further accelerating demand. Overall, the market is supported by cost-effective, scalable solutions and growing awareness of humane animal management practices.

To know about the assumptions considered for the study download the pdf brochure

Prominent players in the Europe veterinary castration market include Zoetis (US) and Virbac (France). These players have expanded their market share through targeted strategies. Zoetis focuses on immunocastration with products such as Improvac, leveraging strong distribution, regulatory approvals, and livestock penetration. Virbac drives growth in companion animals through implants such as Suprelorin, supported by veterinary engagement and demand for minimally invasive solutions.

• In October 2024, Zoetis completed the divestiture of its medicated feed additive (MFA) portfolio to Phibro Animal Health, sharpening its strategic focus on vaccines, biologics, and genetic programs in livestock categories that directly encompass Improvac, its flagship immunocastration product for swine.
• In June 2022, the European Union approved Suprelorin use for male cats and prepubescent female dogs, expanding options for veterinarians to meet evolving owner expectations and animal care needs.

Zoetis (US)

Zoetis is a global animal health company engaged in developing and commercializing veterinary medicines and vaccines for companion animals and livestock. Its portfolio includes reproductive health solutions, including immunocastration products widely used in the livestock sector. The company operates in more than 100 countries, including major European markets, supporting the Europe veterinary castration market through non-surgical solutions, particularly for swine production, driven by regulatory shifts toward animal welfare compliance.

Virbac (France)

Virbac is a global veterinary pharmaceutical company offering medicines, vaccines, and animal health solutions for companion animals and livestock. In the Europe veterinary castration market, it is a key player through the Suprelorin implant, a reversible non-surgical castration solution for dogs and cats. The company operates in more than 100 countries, with a strong presence in Europe, supporting the growing demand for humane sterilization methods.

Market Ranking

The Europe veterinary castration market is consolidated and led by major players, including Zoetis (US) and Virbac (France), holding the largest market shares. These leading companies have strong global networks and well-established distribution channels in European countries. Leading companies maintain their market position through strategic partnerships, strong research and development capabilities, and established brand presence. In contrast, smaller players focus on offering cost-effective products and developing innovative technologies. As a result, the market includes both large global companies and agile, regionally focused competitors.

Related Reports:

Europe Veterinary Castration Market By Product Type (Immunocastration Vaccines, Hormonal Implants), Animal Type (Companion Dogs, Stray Dogs, Companion Cats, Stray Cats, Swine), End User (Veterinary Clinics, Veterinary Hospitals, NGOs) - Forecast to 2032

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]